HomeCompareGNHAY vs EPRT

GNHAY vs EPRT: Dividend Comparison 2026

GNHAY yields 5.29% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNHAY wins by $6.18M in total portfolio value
10 years
GNHAY
GNHAY
● Live price
5.29%
Share price
$38.39
Annual div
$2.03
5Y div CAGR
62.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.25M
Annual income
$4,849,407.89
Full GNHAY calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — GNHAY vs EPRT

📍 GNHAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNHAYEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNHAY + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNHAY pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNHAY
Annual income on $10K today (after 15% tax)
$449.27/yr
After 10yr DRIP, annual income (after tax)
$4,121,996.71/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, GNHAY beats the other by $4,111,082.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNHAY + EPRT for your $10,000?

GNHAY: 50%EPRT: 50%
100% EPRT50/50100% GNHAY
Portfolio after 10yr
$3.15M
Annual income
$2,431,124.31/yr
Blended yield
77.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

GNHAY
No analyst data
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNHAY buys
0
EPRT buys
0
No recent congressional trades found for GNHAY or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNHAYEPRT
Forward yield5.29%3.92%
Annual dividend / share$2.03$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR62.6%29%
Portfolio after 10y$6.25M$63.4K
Annual income after 10y$4,849,407.89$12,840.73
Total dividends collected$6.10M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: GNHAY vs EPRT ($10,000, DRIP)

YearGNHAY PortfolioGNHAY Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$11,559$859.42$11,205$505.18+$354.00GNHAY
2$13,878$1,509.66$12,672$682.46+$1.2KGNHAY
3$17,604$2,754.33$14,490$930.48+$3.1KGNHAY
4$24,146$5,309.21$16,786$1,282.69+$7.4KGNHAY
5$36,902$11,066.02$19,753$1,791.56+$17.1KGNHAY
6$65,185$25,700.29$23,677$2,541.64+$41.5KGNHAY
7$138,737$68,988.48$29,008$3,672.99+$109.7KGNHAY
8$371,577$223,128.79$36,463$5,425.08+$335.1KGNHAY
9$1,305,722$908,134.35$47,238$8,221.57+$1.26MGNHAY
10$6,246,530$4,849,407.89$63,385$12,840.73+$6.18MGNHAY

GNHAY vs EPRT: Complete Analysis 2026

GNHAYStock

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of March 22, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.

Full GNHAY Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this GNHAY vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNHAY vs SCHDGNHAY vs JEPIGNHAY vs OGNHAY vs KOGNHAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.